MX2022004144A - Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3. - Google Patents
Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.Info
- Publication number
- MX2022004144A MX2022004144A MX2022004144A MX2022004144A MX2022004144A MX 2022004144 A MX2022004144 A MX 2022004144A MX 2022004144 A MX2022004144 A MX 2022004144A MX 2022004144 A MX2022004144 A MX 2022004144A MX 2022004144 A MX2022004144 A MX 2022004144A
- Authority
- MX
- Mexico
- Prior art keywords
- heterobycyclic
- blockers
- potassium channel
- aryl compounds
- shaker type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962911642P | 2019-10-07 | 2019-10-07 | |
| PCT/US2020/054348 WO2021071803A1 (en) | 2019-10-07 | 2020-10-06 | Aryl heterobicyclic compounds as kv1.3 potassium shaker channel blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022004144A true MX2022004144A (es) | 2022-06-14 |
Family
ID=75436850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022004144A MX2022004144A (es) | 2019-10-07 | 2020-10-06 | Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230040182A1 (enExample) |
| EP (1) | EP4041408A4 (enExample) |
| JP (1) | JP7780439B2 (enExample) |
| KR (1) | KR20220079575A (enExample) |
| CN (1) | CN114728177B (enExample) |
| AU (1) | AU2020363354A1 (enExample) |
| BR (1) | BR112022006250A2 (enExample) |
| CA (1) | CA3156981C (enExample) |
| IL (1) | IL291867A (enExample) |
| MX (1) | MX2022004144A (enExample) |
| WO (1) | WO2021071803A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116782894A (zh) | 2020-10-06 | 2023-09-19 | D.E.肖研究有限责任公司 | 作为Kv1.3钾Shaker通道阻断剂的内酰胺化合物 |
| CN114437070A (zh) * | 2022-01-19 | 2022-05-06 | 广西-东盟食品检验检测中心 | 一种他达拉非新型衍生物的制备方法 |
| JP2026513122A (ja) * | 2022-10-28 | 2026-04-23 | 上海深勢唯思科技有限責任公司 | 芳香族複素環式Ｋｖ１．３阻害剤、その製造方法及び用途 |
| WO2025029769A1 (en) | 2023-07-31 | 2025-02-06 | Eli Lilly And Company | Solid forms of a kv1.3 potassium shaker channel blockers and method of using the same |
| WO2026021011A1 (zh) * | 2024-07-26 | 2026-01-29 | 浙江海正药业股份有限公司 | 芳基三环类衍生物及其制备方法和用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6365615B1 (en) * | 1999-07-21 | 2002-04-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
| US6348486B1 (en) | 2000-10-17 | 2002-02-19 | American Home Products Corporation | Methods for modulating bladder function |
| US6939968B2 (en) | 2002-12-23 | 2005-09-06 | Bristol-Myers Squibb Company | Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives |
| CN1856477A (zh) | 2003-09-23 | 2006-11-01 | 默克公司 | 异喹啉钾通道抑制剂 |
| CN100530013C (zh) * | 2005-03-04 | 2009-08-19 | 松下电器产业株式会社 | 电子设备控制装置及其控制方法 |
| US7538110B2 (en) * | 2005-10-27 | 2009-05-26 | Adolor Corporation | Opioid antagonists |
| US8124636B2 (en) * | 2008-04-30 | 2012-02-28 | Hoffmann-La Roche Inc. | Imidazolidinone derivatives as 11B-HSD1 inhibitors |
| TW201026708A (en) * | 2008-12-12 | 2010-07-16 | Solvay Pharm Bv | Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers |
| WO2011073273A1 (en) | 2009-12-16 | 2011-06-23 | Evotec Ag | Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators |
| US20120065210A1 (en) * | 2010-09-15 | 2012-03-15 | Xin-Jie Chu | Substituted hexahydropyrrolo[1,2-c]imidazolones |
| TWI698438B (zh) * | 2015-03-13 | 2020-07-11 | 德商４Ｓｃ製藥公司 | Ｋv１.３抑制劑及其醫學應用 |
-
2020
- 2020-10-06 IL IL291867A patent/IL291867A/en unknown
- 2020-10-06 CA CA3156981A patent/CA3156981C/en active Active
- 2020-10-06 WO PCT/US2020/054348 patent/WO2021071803A1/en not_active Ceased
- 2020-10-06 JP JP2022546588A patent/JP7780439B2/ja active Active
- 2020-10-06 BR BR112022006250A patent/BR112022006250A2/pt not_active IP Right Cessation
- 2020-10-06 AU AU2020363354A patent/AU2020363354A1/en not_active Abandoned
- 2020-10-06 MX MX2022004144A patent/MX2022004144A/es unknown
- 2020-10-06 EP EP20874328.6A patent/EP4041408A4/en active Pending
- 2020-10-06 US US17/766,837 patent/US20230040182A1/en not_active Abandoned
- 2020-10-06 CN CN202080084476.1A patent/CN114728177B/zh active Active
- 2020-10-06 KR KR1020227013493A patent/KR20220079575A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021071803A1 (en) | 2021-04-15 |
| CN114728177B (zh) | 2025-06-24 |
| EP4041408A1 (en) | 2022-08-17 |
| US20230040182A1 (en) | 2023-02-09 |
| AU2020363354A1 (en) | 2022-04-21 |
| KR20220079575A (ko) | 2022-06-13 |
| BR112022006250A2 (pt) | 2022-06-21 |
| JP7780439B2 (ja) | 2025-12-04 |
| CN114728177A (zh) | 2022-07-08 |
| CA3156981A1 (en) | 2021-04-15 |
| JP2022550641A (ja) | 2022-12-02 |
| IL291867A (en) | 2022-06-01 |
| EP4041408A4 (en) | 2023-10-18 |
| CA3156981C (en) | 2025-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022004127A (es) | Compuestos heterociclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3. | |
| ECSP22046699A (es) | Inhibidores de kras g12c | |
| CO2022004305A2 (es) | Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3 | |
| MX2022004168A (es) | Compuestos aromaticos de arilmetileno a manera de bloqueadores del canal de potasio kv1.3. | |
| CL2020003007A1 (es) | Lactamas biciclicas y metodos de uso de las mismas (divisional solicitud no. 3486-2017) | |
| MX2022004178A (es) | Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3. | |
| CY1122821T1 (el) | Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2 | |
| MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
| MX386103B (es) | Inhibidores de mcl-1 y metodos de uso de los mismos. | |
| MX2022005160A (es) | Oxisteroles y metodos de uso de los mismos. | |
| CO2023016088A2 (es) | Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3 | |
| MX392270B (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| CO2022002336A2 (es) | Compuestos heterocíclicos | |
| MX2020010949A (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas. | |
| CR20210014A (es) | Derivados de pirrolo [1,2-b] piridazina | |
| CL2023002908A1 (es) | Compuestos heterocíclicos de arilo como bloqueadores del canal agitador de potasio kv1.3 | |
| MX2021002260A (es) | Compuestos utiles como moduladores de la autofagia mediada por chaperonas. | |
| CL2020000439A1 (es) | Sales de un compuesto y sus formas cristalinas. | |
| CO2022006942A2 (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria | |
| MX2022004145A (es) | Compuestos heterociclicos de arilmetileno como bloqueadores del canal de potasio tipo shaker kv1.3. | |
| CO2024006398A2 (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno | |
| UY38498A (es) | Inhibidores de o-glucoproteina-2- acetamido-2-desoxi-3-d-glucopiranosidasa de morfolinilo , piperazinilo , oxazepanilo y diazepanilo | |
| CO2023015732A2 (es) | Moduladores de trex1 | |
| CO2021002415A2 (es) | Derivados de heteroarilo bicíclicos | |
| MX2018006572A (es) | Compuestos. |